BlackRock
IMNM icon

BlackRock’s Immunome IMNM Stock Holding History

BlackRock’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187M Buy
8,805,492
+636,818
+8% +$13.6M ﹤0.01% 1837
2026
Q1 		$179M Buy
8,168,674
+573,678
+8% +$12.8M ﹤0.01% 1750
2025
Q4 		$163M Buy
7,594,996
+1,772,260
+30% +$31.1M ﹤0.01% 1818
2025
Q3 		$68.2M Buy
5,822,736
+52,044
+0.9% +$518K ﹤0.01% 2317
2025
Q2 		$53.7M Buy
5,770,692
+107,993
+2% +$885K ﹤0.01% 2410
2025
Q1 		$38.1M Buy
5,662,699
+1,537,711
+37% +$14.8M ﹤0.01% 2524
2024
Q4 		$43.8M Buy
4,124,988
+143,206
+4% +$1.73M ﹤0.01% 2532
2024
Q3 		$58.2M Buy
3,981,782
+222,918
+6% +$3.17M ﹤0.01% 2378
2024
Q2 		$45.5M Buy
3,758,864
+2,929,851
+353% +$45.8M ﹤0.01% 2466
2024
Q1 		$20.5M Buy
829,013
+438,377
+112% +$8.9M ﹤0.01% 2986
2023
Q4 		$4.18M Buy
390,636
+348,107
+819% +$2.89M ﹤0.01% 3756
2023
Q3 		$355K Sell
42,529
-783
-2% -$5.75K ﹤0.01% 4516
2023
Q2 		$343K Buy
43,312
+1,773
+4% +$9.7K ﹤0.01% 4594
2023
Q1 		$207K Sell
41,539
-429
-1% -$2.1K ﹤0.01% 4759
2022
Q4 		$92.7K Buy
41,968
+516
+1% +$2.08K ﹤0.01% 5066
2022
Q3 		$183K Buy
41,452
+2,241
+6% +$10.5K ﹤0.01% 4998
2022
Q2 		$126K Sell
39,211
-357
-0.9% -$1.3K ﹤0.01% 5168
2022
Q1 		$224K Sell
39,568
-1,071
-3% -$8.01K ﹤0.01% 5082
2021
Q4 		$527K Buy
40,639
+131
+0.3% +$2.34K ﹤0.01% 4854
2021
Q3 		$986K Buy
40,508
+17,622
+77% +$307K ﹤0.01% 4562
2021
Q2 		$396K Sell
22,886
-89,965
-80% -$1.99M ﹤0.01% 4750
2021
Q1 		$3.82M Buy
112,851
+41,099
+57% +$1.02M ﹤0.01% 4061
2020
Q4 		$695K Buy
+71,752
New +$837K ﹤0.01% 4290

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's IMNM Position: Q2 2026 in Review

BlackRock increased its Immunome (IMNM) stake by 7.8% in Q2 2026, buying an estimated $13.6M and bringing the position to 8,805,492 shares worth $187M. The position accounts for ﹤0.01% of the portfolio, ranked #1837.

BlackRock first reported a position in IMNM in Q4 2020 and has held it in 23 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • BlackRock held 8,805,492 shares of Immunome worth $187M as of Q2 2026.
  • BlackRock bought 636,818 Immunome shares in Q2 2026, an estimated $13.6M.
  • Immunome made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1837 holding.
  • BlackRock first reported a position in Immunome in Q4 2020 and has held it in 23 quarters since.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.